Procter & Gamble Health Ltd (PGHL) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 500126 | NSE: PGHL | Pharmaceuticals & Drugs | Small Cap

Procter&Gamble Healt Share Price

5,750 -96.40 -1.65%
as on 05-Dec'25 12:17

Procter & Gamble Health Ltd (PGHL) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 500126 | NSE: PGHL | Pharmaceuticals & Drugs | Small Cap

DeciZen - make an informed investing decision on Procter&Gamble Healt

Based on:

Overall Rating
Login to view analysis. Bole Toh

1. Quality


Login to view analysis.

2. Valuation


Login to view analysis.

3. Price Trend


Login to view analysis.

Procter & Gamble Health stock performance -

Key Ratios
mw4me loader
P/E Ratio (SA):
31.63
Market Cap:
9,704.7 Cr.
52-wk low:
4,916
52-wk high:
6,700

Is Procter & Gamble Health Ltd an attractive stock to invest in?


Login to view analysis.

10 Year X-Ray of Procter&Gamble Healt: Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Procter & Gamble Health Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation

Value Creation Index Colour Code Guide

Dec'16Dec'17Dec'18Jun'20Jun'21Jun'22Jun'23Mar'24Jun'24Mar'25TTM
ROCE % 18.4%14.2%13.9%29%29.1%38.5%46.1%0%42.5%58.1%-
Value Creation
Index
0.30.00.01.21.21.92.4NA2.23.3-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 9936988499041,0091,1141,2301,1511,1511,2461,284
Sales YoY Gr.--29.7%21.6%6.5%11.6%10.5%10.3%-6.4%0%8.2%-
Adj EPS 46.628.858.1102.2107.1116.5137.8129.7129.7188.5184.8
YoY Gr.--38.3%102.1%75.9%4.8%8.8%18.3%-5.9%0%45.3%-
BVPS (₹) 399.9441.7927.8363.2421.6367447.6319.1319.1427.4373.3
Adj Net
Profit
77.447.896.5170178193229215215313307
Cash Flow from Ops. 10753.7-130157247170236228228225-
Debt/CF from Ops. 0000000000-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 2.6%4.3%0.4%8.2%
Adj EPS 16.8%12%11%45.3%
BVPS0.7%0.3%-1.5%33.9%
Share Price 22.1% -3.4% 11.8% 2.6%

Key Financial Parameters

Performance Ratio Colour Code Guide

Dec'16Dec'17Dec'18Jun'20Jun'21Jun'22Jun'23Mar'24Jun'24Mar'25TTM
Return on
Equity %
12.36.88.520.822.129.333.533.433.443.646.2
Op. Profit
Mgn %
11.710.11723.424.524.126.426.626.634.132.3
Net Profit
Mgn %
7.86.811.418.817.617.418.618.718.725.123.9
Debt to
Equity
00000000000
Working Cap
Days
367503486346491438423290290146127
Cash Conv.
Cycle
66884912-3-22-31-33-33-3680

Recent Performance Summary

Login to view analysis.
Login to view analysis.

Latest Financials - Procter & Gamble Health Ltd.

Standalone Consolidated
TTM EPS (₹) 184.8 -
TTM Sales (₹ Cr.) 1,284 -
BVPS (₹.) 373.3 -
Reserves (₹ Cr.) 603 -
P/BV 15.66 -
PE 31.63 -
From the Market
52 Week Low / High (₹) 4916.00 / 6700.00
All Time Low / High (₹) 114.00 / 7499.95
Market Cap (₹ Cr.) 9,705
Equity (₹ Cr.) 16.6
Face Value (₹) 10
Industry PE 40.7

Management X-Ray of Procter&Gamble Healt:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Procter&Gamble Healt - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios of Procter&Gamble Healt

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSDec'15Dec'16Dec'17Dec'18Jun'20Jun'21Jun'22Jun'23Jun'24Mar'25
Sales9409936988491,3561,0091,1141,2301,151934
Operating Expenses 8568776287051,042763847905845616
Manufacturing Costs8673818514013914713912287
Material Costs437412237269431312340362331263
Employee Cost 123154110131183154168206215142
Other Costs 210238200220287158193198178124
Operating Profit 8311671144314246268325306318
Operating Profit Margin (%) 8.9%11.6%10.1%17.0%23.2%24.4%24.0%26.4%26.6%34.1%
Other Income 23243028701813181610
Interest 0000010110
Depreciation 23251921293027282717
Exceptional Items 001770000-200
Profit Before Tax 8311599158355233253314273312
Tax 303638561015661857277
Profit After Tax 547961102254177193229201234
PAT Margin (%) 5.7%8.0%8.7%12.0%18.7%17.5%17.3%18.7%17.5%25.1%
Adjusted EPS (₹)32.347.736.861.3153.1106.5116.0138.2121.1141.2
Dividend Payout Ratio (%)23%23%41%718%150%122%45%69%215%89%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSDec'15Dec'16Dec'17Dec'18Jun'20Jun'21Jun'22Jun'23Jun'24Mar'25

Equity and Liabilities

Shareholders Fund 5926647331,540904700609743530532
Share Capital 17171717171717171717
Reserves 5756477171,524888683593726513515
Minority Interest0000000000
Debt0000000000
Long Term Debt0000000000
Short Term Debt0000000000
Trade Payables66758391124179172237167172
Others Liabilities 8686246999511,0841,0991,1571,2536455
Total Liabilities 1,5251,3631,5162,5832,1121,9781,9382,233761759

Fixed Assets

Gross Block271144192186200215241263223222
Accumulated Depreciation14025516110211413112197110
Net Fixed Assets 13211914012498101110142127112
CWIP 73091721394132611
Investments 4228700000000
Inventories167164158113134118115135109109
Trade Receivables1271071236695608311685145
Cash Equivalents 1882792781,243639469325440244189
Others Assets 8636367381,0181,1241,1911,2641,368189193
Total Assets 1,5251,3631,5162,5832,1121,9781,9382,233761759

Cash Flow

(All Figures are in Crores.)
PARTICULARSDec'15Dec'16Dec'17Dec'18Jun'20Jun'21Jun'22Jun'23Jun'24Mar'25
Cash Flow From Operating Activity 8310754-130235247170236228169
PBT 831151521,138355233253314273312
Adjustment 16158-914-124127415212
Changes in Working Capital 1630-47-50-641-47-30-12-74
Tax Paid -32-53-60-304-102-68-64-90-85-81
Cash Flow From Investing Activity -68-75-481,270165-32-26-22-710
Capex -45-32-10-19-23-51-38-38-22-1
Net Investments -39-59-5721412400000
Others 1616201,075641912161510
Cash Flow From Financing Activity -12-15-22-30-883-387-289-98-418-235
Net Proceeds from Shares 0000000000
Net Proceeds from Borrowing 0000000000
Interest Paid 0000000000
Dividend Paid -10-12-18-25-733-382-284-94-415-232
Others -2-3-4-5-150-5-5-5-3-2
Net Cash Flow 417-161,109-483-172-145116-197-56

Finance Ratio

PARTICULARSDec'15Dec'16Dec'17Dec'18Jun'20Jun'21Jun'22Jun'23Jun'24Mar'25
Ratios
ROE (%)9.3512.618.748.9520.7922.0429.4133.9431.5844.15
ROCE (%)14.5418.3514.1613.929.0129.0838.4546.0742.5258.05
Asset Turnover Ratio0.710.710.490.410.580.490.60.640.841.35
PAT to CFO Conversion(x)1.541.350.89-1.270.931.40.881.031.130.72
Working Capital Days
Receivable Days43415941222822272941
Inventory Days64598358334636343539
Payable Days456111811691177189206223235

Procter & Gamble Health Ltd Stock News

Procter & Gamble Health Ltd FAQs

The current trading price of Procter&Gamble Healt on 05-Dec-2025 12:17 is ₹5,750.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 04-Dec-2025 the market cap of Procter&Gamble Healt stood at ₹9,704.7.
The latest P/E ratio of Procter&Gamble Healt as of 04-Dec-2025 is 31.63.
The latest P/B ratio of Procter&Gamble Healt as of 04-Dec-2025 is 15.66.
The 52-week high of Procter&Gamble Healt is ₹6,700 and the 52-week low is ₹4,916.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Procter&Gamble Healt is ₹1,284 ( Cr.) .

About Procter & Gamble Health Ltd

Procter & Gamble Health Limited (formerly Merck Limited) was set up in India as one of Merck’s Asian subsidiaries in 1967.  It was also the first Merck Group Company to go public in the year 1981.  Till 2018, the Company was operating in all businesses included in the pharmaceuticals and chemicals businesses in the country.

On December 1st, 2018, P&G successfully completed the acquisition of Merck’s Consumer Health business further to approval of all relevant regulatory authorities and the fulfilment of other customary closing conditions. Procter & Gamble Overseas India B.V. now holds 51.81% of the share capital in Merck Limited, while the remaining 48.19% is traded on the Bombay Stock Exchange Ltd. and National Stock Exchange of India Ltd.

Currently, Procter & Gamble Health Limited (formerly Merck Limited) is one of India’s largest VMS Companies manufacturing and marketing over-the-counter products, vitamins, minerals, and supplements products for a healthy lifestyle and improved quality of life. Its trusted products are household names in India protecting and supporting millions of people at every stage of life. With a strong portfolio of brands backed by science and trusted by doctors, pharmacists and consumers, Procter & Gamble Health Limited combines the best of P&G and Legacy Merck’s Consumer Health capabilities and cultures. Together we are working towards leveraging our combined expertise to develop categories and brands that meet today’s needs and tomorrow’s opportunities.

Situated at Usgaon, Goa, the company’s Manufacturing Site has grown from a small Vitamin E producing unit to a big composite plant manufacturing pharma and chemical products.

Business area of the company

Till 2018, the Company was operating in all businesses included in the pharmaceuticals and chemicals businesses in the country. The company is one of India’s largest VMS Companies manufacturing and marketing over-the-counter products, vitamins, minerals, and supplements products for a healthy lifestyle and improved quality of life. Its trusted products are household names in India protecting and supporting millions of people at every stage of life.

Brands of the company

  • Neurobion
  • Evion
  • Seven Seas
  • Nasivion
  • Polybion
  • Livogen

Awards and achievements

  • 2015-16: Merck Goa plant was awarded 1st prize in safety called “Gomant Sarvochcha Suraksha Puraskar”. This is consecutive 2nd time Merck Goa plant bagged 1st prize in safety. Prior to that Merck Goa plant bagged 2nd prize in safety “Gomant Uchcha Suraksha Puraskar” for two consecutive years.
  • 2016-17: Consumer activation done for Neurobion under ‘True Heroes’ campaign won laurels at the Global level to receive President’s Award in 2017.
  • 2017-18: Nasivion continued to be the Doctors’ trusted No. 1 Nasal Decongestant.
  • 2019-20: Neurobion bagged three awards viz. Nicholas Hall Marketing Excellence Award; CIMS Trusted Brand of the Year; and ABP News Brand Excellence Award.
To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×